Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024
Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024
SAN MATEO, Calif., May 2, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2024 financial results after market close on Tuesday, May 14, 2024, then host a live webcast and conference call at 4:30 p.m. Eastern Daylight Time/1:30 p.m. Pacific Daylight Time to discuss the results and provide an update on the Company's business.
加利福尼亞州聖馬特奧，2024年5月2日 /PRNewswire/ — 專注於開發和商業化用於醫療監管環境的創新療法的專業製藥公司Talphera, Inc.（納斯達克股票代碼：TLPH）（“Talphera”）今天宣佈，將在2024年5月14日星期二收盤後發佈2024年第一季度財務業績，然後在4點舉辦網絡直播和電話會議美國東部夏令時間下午 3:30 /太平洋夏令時間下午 1:30 討論結果並提供公司業務的最新情況。
Webcast Information
網絡直播信息
The webcast can be accessed here or by visiting the Investors section of the Company's website at and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event.
可以在此處訪問網絡直播，也可以訪問公司網站的 “投資者” 部分，然後單擊 “投資者/新聞與活動/即將舉行的活動” 部分中發佈的網絡直播鏈接。網絡直播將包括幻燈片演示，重播將在活動結束後的90天內在Talphera網站上播放。
Conference Call Information
電話會議信息
Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside of Canada. The conference ID is 79169.
希望參加電話會議的投資者可以撥打1-800-836-8184的北美來電者，或撥打1-646-357-8785（收費）（適用於加拿大以外的國際來電者）。會議 ID 是 79169。
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe. This release is intended for investors only. For additional information about Talphera, please visit .
關於 Talphera, Inc.
Talphera, Inc. 是一家專業製藥公司，專注於用於醫療監管環境的創新療法的開發和商業化。Talphera 的主要候選產品 Niyad，是那法莫司他的一種凍乾製劑，目前正在研究設備豁免（IDE）下作爲體外迴路的抗凝劑進行研究，並已獲得美國食品藥品管理局的突破性設備認證。Talphera還在開發兩款已獲得其合作伙伴Aguettant許可的預充注射器：Fedsyra，一種預先填充的麻黃鹼注射器，以及 PFS-02，一種預填充的去氧腎上腺素注射器。本新聞稿僅適用於投資者。如需了解有關 Talphera 的更多信息，請訪問。
SOURCE Talphera, Inc.
來源 Talphera, Inc.
譯文內容由第三人軟體翻譯。